Q-omics provides the consensus-scored RAPGEF5 profile across patient tissues and cancer cell-line models. RAPGEF5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAPGEF5 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RAPGEF5 RNA expression shows 20,915 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where RAPGEF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAPGEF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAPGEF5 survival associations across molecular data types. RAPGEF5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAPGEF5 RNA expression–survival associations across cancer types. High RAPGEF5 expression shows unfavorable associations in UCEC, BLCA and STAD, but favorable associations in KIRC, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAPGEF5 RNA expression.
This table summarizes RAPGEF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAPGEF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAPGEF5 shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in KIRC, THCA and STAD. The KIRC box plot shows higher RAPGEF5 RNA expression in tumor versus normal tissue (log2 FC = +1.127, t-test p < 0.001).
This table shows molecular features associated with RAPGEF5 in patient tissues and cancer cell lines. In patient samples, RAPGEF5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAPGEF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
